Dosing is underway in a Phase 1 dose-escalation study evaluating Agenus’ (NASDAQ:AGEN) AGEN1181 in patients with advanced solid tumors.
The first participants will receive AGEN1181 alone and in combination with a PD-1 inhibitor [AGEN2034 (balstilimab)].
AGEN1181 is an “Fc engineered” anti-CTLA-4 monoclonal antibody that binds to an Fc receptor, FcγRIIIA, found on antigen-presenting cells or natural killer cells, enhancing the therapeutic potential of anti-CTLA-4 therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.